2024 Repligen corp stock - Apr 25, 2023 · Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today.

 
7.05%. Trailing 12-Months. The Repligen Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.. Repligen corp stock

Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.Apr 25, 2023 · Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%. Repligen Corp stock has a Value Score of 4, Growth Score of 82 and Estimate Revisions Score of 38. Comparing Avantor Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ. On October 17, 2023, Repligen Corp (RGEN) stock showed promising performances, with a median target price forecast of $195.00 by 13 analysts. This represents a potential increase of 33.96% from the last recorded price of $145.57. The high estimate for the stock price is $240.00, while the low estimate is $165.00.7.05%. Trailing 12-Months. The Repligen Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Discover historical prices for RGEN stock on Yahoo Finance. View daily, weekly or monthly format back to when Repligen Corporation stock was issued. The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Medtronic PLC. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their portfolio.Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of …With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of …Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected] the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Nov 9, 2023 · Summary. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. Repligen Corporation to Present at Upcoming Investor Conferences. Nov. 07. AQ. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Repligen Corporation Common Stock (RGEN) Stock Price, Quote, News & History | Nasdaq MY QUOTES: RGEN Edit my quotes Repligen Corporation Common Stock (RGEN) 0 Add to Watchlist...Nov 24, 2023 · In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%. Financial Statements. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp stock has a Value Score of 4, Growth Score of 82 and Estimate Revisions Score of 38. Comparing Avantor Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Detailed statistics for Repligen Corporation (RGEN) stock, including valuation metrics, financial numbers, share information and more.Repligen Corp’s ( RGEN) price is currently up 23.95% so far this month. During the month of July, Repligen Corp’s stock price has reached a high of $177.18 and a low of $134.64. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $134.64. Year to date, Repligen Corp’s stock is down 33.79%.Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%.Repligen Corp., which was founded by Alexander G., provides bioprocessing technologies and services utilized in producing biological drugs. ... With institutions owning 91% of its stock, it’s clear that Repligen is attracting some serious attention from experienced and savvy investors who see its potential for growth in the biotech sector ...Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 37 and Quality Score of 71. Comparing Bio Rad Laboratories Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well …Repligen Corp (RGEN) Stock Shows Positive Performance and Promising Price Forecasts in the Biopharmaceutical Industry. On November 2, 2023, Repligen Corp (RGEN) experienced positive stock performance, with analysts forecasting a potential increase in its stock price. According to data from CNN Money, there are 13 analysts …Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 41. Comparing Premier Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.See Insiders’ Hot Stocks on TipRanks >> Based on Repligen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $182.66 million and a net ...Within the last quarter, Repligen (NASDAQ:RGEN) has observed the following analyst ratings: According to 7 analyst offering 12-month price targets in the last …Dec 4, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 81.2. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens; A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas; AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount; Dividend Investing Newsletter and model …Repligen does not undertake to update, ... 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 ...Jul 21, 2023 · Repligen Corp’s ( RGEN) price is currently up 23.95% so far this month. During the month of July, Repligen Corp’s stock price has reached a high of $177.18 and a low of $134.64. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $134.64. Year to date, Repligen Corp’s stock is down 33.79%. RGEN stock, belonging to Repligen Corp, has shown promising performance on October 31, 2023, based on the information provided. The data source for this analysis is CNN Money. According to the 13 analysts, the median target price for Repligen Corp is $195.00. The high estimate is $240.00, while the low estimate stands …Repligen Corp (NASDAQ:RGEN) · Advanced Chart · U.S · World · Politics · Business · Opinion · Health · Entertainment · Stars · Screen · Binge · Culture &midd...Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 10.83% in the past year. Currently, Repligen Corp’s price-earnings ratio is 50.0. Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%.Repligen Corp., the recipient of this investment, is a global life sciences company specializing in providing bioprocessing technologies and solutions used in manufacturing biological drugs. ... While Repligen’s stock opened at $156.63 on Friday, the company had a market capitalization of $8.72 billion, with a beta of 1.08, and PE ratio of …The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ...Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen …America’s largest Marine Corps bases include North Carolina’s Marine Corps Base Camp Lejeune, and California’s Marine Corps Air Ground Combat Center Twentynine Palms and Marine Corps Base Camp Pendleton.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Medtronic PLC. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their portfolio.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.11 brokers have issued 12-month price targets for Repligen's stock. Their RGEN share price targets range from $165.00 to $210.00. On average, they expect the company's share price to reach $189.55 in the next year. This suggests a possible upside of 19.5% from the stock's current price.On average, Wall Street analysts predict. that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a potential upside of 25.33% from the current RGEN share price of $150.60.CureVac N.V. -0.54%. $1.23B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Nov 7, 2023 · Repligen Corp Stock Price History. Repligen Corp’s price is currently up 12.18% so far this month. During the month of November, Repligen Corp’s stock price has reached a high of $152.22 and a low of $126.86. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $110.45. Year to date, Repligen Corp’s stock is ... Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%.Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.On average, Wall Street analysts predict that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a ...Repligen Corp (NASDAQ:RGEN) 157.02 Delayed Data As of Nov 21 +1.38 / +0.89% Today’s Change 110.45 Today ||| 52-Week Range 200.98 -7.26% Year-to-Date Quote …Find the latest Repligen Corporation (RGN.F) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Repligen Corporation (NASDAQ:RGEN) Q3 ...The share price of Repligen Corp. (NASDAQ:RGEN) dipped -2.38% to close Friday’s market session at $119.58, lower as compared to yesterday’s close. The stock price fluctuated between $118.08 and $122.45 throughout the trading session with the volume trading being 788849 shares, which represented a significant variation when …See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 48.1. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected]:MUN Munich Stock Exchange; RGN:STU Stuttgart Stock Exchange; RGEN:DEU German Composite; RGN:FRA Frankfurt Stock Exchange; RGN:DUS Dusseldorf Stock Exchange; ... Repligen Corp BUILDING 1, SUITE 100, 41 SEYON STREET WALTHAM 02453 United States USA; Phone +1 (781) 449-9560; Fax +1 (302) …Aug 3, 2023 · Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract ... Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs.Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock...Repligen Corp stock has a Value Score of 6, Growth Score of 82 and Estimate Revisions Score of 38. Comparing West Pharmaceutical Services Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset …WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for ...Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price.The stock’s lowest price was $157.58 before closing at $157.00. Repligen Corp. experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $200.98 on 02/16/23, while the lowest price for the same period was registered at $110.45 on 10/30/23.4 thg 4, 2016 ... Once you've won approval for a biologic, or biosimilar, manufactured at a particular facility, you can't just switch to another without jumping ...RGEN: Repligen Corp Stock Price Quote - NASDAQ GS - Bloomberg Back Forward Markets Data Repligen Corp RGEN:US Nasdaq GS (USD) As of 12:00 AM …Oct 30, 2023 · Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA. RGN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock ...Dec 2, 2023 · With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of $0.78 in Dec 31, 1997 . If you had invested in Repligen stock at $0.78 , your return over the last 25 years would have been 21,019.08% , for an annualized return of 23.88% (not ... Dec 4, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 81.2. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp stock has a Value Score of 6, Growth Score of 82 and Estimate Revisions Score of 38. Comparing West Pharmaceutical Services Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset …You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.7.05%. Trailing 12-Months. The Repligen Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.One analyst has given the Repligen stock a sell rating, while five others have issued a buy rating on the firm, providing investors with mixed opinions regarding investment in this potentially promising industry player. ... Repligen Corp., a global life sciences company, has been making headlines recently with changes in ratings and price ...Repligen corp stock

In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%. Financial Statements.. Repligen corp stock

repligen corp stock

We explain indepth Repligen Corp financials and how to pick the best broker to invest Repligen Corp stocks and CFDs with. Comparebrokers.co. Popular. Technology. Zoom (ZM) AMD (AMD) Facebook (FB) Netflix (NFLX) Growing. Apple (AAPL) Tesla (TSLA) Amazon (AMZN) Astrazeneca PLC (AZN) Economy.www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2]Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...Find real-time RGEN - Repligen Corp stock quotes, company profile, news and forecasts from CNN Business. Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of …45.97M. 305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed …Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock...One analyst has given the Repligen stock a sell rating, while five others have issued a buy rating on the firm, providing investors with mixed opinions regarding investment in this potentially promising industry player. ... Repligen Corp., a global life sciences company, has been making headlines recently with changes in ratings and price ...Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price. The current consensus among 14 polled investment analysts is to buy stock in Repligen Corp. This rating has held steady since August, indicating a consistent belief in the company’s potential for growth. Repligen Corp has reported strong financials for the current quarter, with earnings per share of $0.55 and sales of $179.5 million.Discover historical prices for RGEN stock on Yahoo Finance. View daily, weekly or monthly format back to when Repligen Corporation stock was issued. Repligen Announces Publication of the Company’s 2022 Sustainability Report November 14, 2023TipRanks. Repligen price target lowered to $150 from $165 at Deutsche Bank November 7, 2023TipRanks ...RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Discover historical prices for RGEN stock on Yahoo Finance. View daily, weekly or monthly format back to when Repligen Corporation stock was issued. Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! Get market updates, educational videos, webinars, and stock analysis. Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.Read about Repligen Corp (RGEN:XNAS) stock and today's latest news and financial updates. ... Repligen Corp RGEN. Morningstar Rating Unlock. Stock XNAS Rating as of Nov 24, 2023. Summary;Repligen Corporation (NasdaqGS:RGEN) completed the acquisition of Bio-Flex Solutions, L.L.C. / Newton T & M Corp for $31.8 million on December 16, 2021. The purchase price of $31.8 million includes $3 million deposited into an escrow against which the Company may make claims for indemnification.Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. Oct 3, 2023 · Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. Repligen Corp. (US:RGEN) has 1047 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 71,198,355 shares.Repligen Corporation. Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million. Narrows full year revenue guidance to range of $635-$645 million ...Feb 28, 2023 · Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. Analysts expect adjusted earnings to reach $2.678 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare DexCom, Inc. and Repligen Corp Stock ... Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 35 and Quality Score of 70. Comparing Adapthealth Corp and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Corporation Prices Public Offering of Shares of Common Stock. 6/27/2017. Summary. WALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation ...Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract ...As President and CEO at REPLIGEN CORP , Tony J. Hunt made $7,713,930 in total compensation. Of this total $800,000 was received as a salary, $785,440 was received as a bonus, $1,623,698 was received in stock options, $4,499,792 was awarded as stock and $5,000 came from other types of compensation. This information is according to proxy ...Dec 1, 2023 · Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 35 and Quality Score of 70. Comparing Adapthealth Corp and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. Stock analysis for Repligen Corp (RGEN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing ...Repligen Corp stock has a Momentum Score of 57, Estimate Revisions Score of 50 and Quality Score of 73. Comparing DexCom, Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Item 7.01 Regulation FD Disclosure. On April 12, 2023, Repligen Corporation (the "Company") made available an Investor Presentation relating to the FlexBiosys Transaction described in Item 8.01 of this 8-K. A copy of this Investor Presentation is attached to this Current Report on Form 8-K and furnished as Exhibit 99.1.WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch ...Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ...Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. Mar 27, 2023 · During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $157.11. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 36.92%. Avantor Inc does not currently pay a dividend. Currently, Repligen Corp’s price-earnings ratio is 63.2. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.748 per share for the current fiscal ...Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen does not undertake to update, ... 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 ...Find the latest Repligen Corp (RGN.MU) stock quote, history, news and other vital information to help you with your stock trading and investing.Apr 28, 2023 · Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36. Summary. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. Repligen Corporation to Present at Upcoming Investor Conferences. Nov. 07. AQ. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03.Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of …... Stock quotes by finanzen.net · Home · Stocks · Repligen-stock · News for Repligen Repligen. News for Repligen Corp. GlobeNewswire 20d. UPDATE – Repligen ...Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. ... Raising target price to $161.00REPLIGEN CORP has an ... Nov. 14, 2023 ...Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%.Waltham, Massachusetts 02453. Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $801.54M. Net Income $185.96M. 2022 Sales Growth 19.54%.11.55%. Overview. Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, …www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2]Mar 27, 2023 · During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $157.11. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 36.92%. UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of …. Stock market simulators